Human epidermal growth factor receptor 2 as a prognostic indicator in osteogenic sarcoma

Carol D Morris, Richard Gorlick, Andrew G. Huvos, Glenn Heller, Paul A. Meyers, John H. Healey

Research output: Contribution to journalArticle

Abstract

Prognostic biologic factors that can be assessed at the time of diagnosis for patients with osteogenic sarcoma have not been identified. The current study was designed to evaluate the prognostic significance of the human epidermal growth factor receptor 2 as it relates to histologic response to preoperative chemotherapy and event-free survival. A retrospective immunohistochemical study was performed on material from patients who were newly diagnosed with osteogenic sarcoma who were treated according to the T12 protocol from the authors' institution between 1986 to 1993. Staining for HER2/erbB-2 was accomplished using standard monoclonal antibodies and methods. At the time of initial biopsy, 42.6% of the samples showed HER2/erbB-2 overexpression. Higher levels of expression were observed in samples from patients with clinically detectable metastases at initial presentation and at relapse. Expression of HER2/erbB-2 correlated with inferior event-free survival in patients with nonmetastatic disease (47% versus 79% at 5 years). In addition, HER2/erbB-2 expression was associated with significantly less tumor necrosis after preoperative chemotherapy as determined by the Huvos grading system. These data suggest that HER2/erbB-2 should be evaluated prospectively as a prognostic indicator and clinical trials using antibodies that target this receptor should be considered for the treatment of patients with osteogenic sarcoma.

Original languageEnglish (US)
Pages (from-to)59-65
Number of pages7
JournalClinical Orthopaedics and Related Research
Issue number382
StatePublished - 2001
Externally publishedYes

Fingerprint

Osteosarcoma
Disease-Free Survival
Drug Therapy
Biological Factors
Necrosis
Retrospective Studies
Monoclonal Antibodies
human ERBB2 protein
Clinical Trials
Staining and Labeling
Neoplasm Metastasis
Biopsy
Recurrence
Antibodies
Neoplasms

ASJC Scopus subject areas

  • Surgery
  • Orthopedics and Sports Medicine

Cite this

Morris, C. D., Gorlick, R., Huvos, A. G., Heller, G., Meyers, P. A., & Healey, J. H. (2001). Human epidermal growth factor receptor 2 as a prognostic indicator in osteogenic sarcoma. Clinical Orthopaedics and Related Research, (382), 59-65.

Human epidermal growth factor receptor 2 as a prognostic indicator in osteogenic sarcoma. / Morris, Carol D; Gorlick, Richard; Huvos, Andrew G.; Heller, Glenn; Meyers, Paul A.; Healey, John H.

In: Clinical Orthopaedics and Related Research, No. 382, 2001, p. 59-65.

Research output: Contribution to journalArticle

Morris, Carol D ; Gorlick, Richard ; Huvos, Andrew G. ; Heller, Glenn ; Meyers, Paul A. ; Healey, John H. / Human epidermal growth factor receptor 2 as a prognostic indicator in osteogenic sarcoma. In: Clinical Orthopaedics and Related Research. 2001 ; No. 382. pp. 59-65.
@article{b7a538cc73854f58a4caa788a2e9db74,
title = "Human epidermal growth factor receptor 2 as a prognostic indicator in osteogenic sarcoma",
abstract = "Prognostic biologic factors that can be assessed at the time of diagnosis for patients with osteogenic sarcoma have not been identified. The current study was designed to evaluate the prognostic significance of the human epidermal growth factor receptor 2 as it relates to histologic response to preoperative chemotherapy and event-free survival. A retrospective immunohistochemical study was performed on material from patients who were newly diagnosed with osteogenic sarcoma who were treated according to the T12 protocol from the authors' institution between 1986 to 1993. Staining for HER2/erbB-2 was accomplished using standard monoclonal antibodies and methods. At the time of initial biopsy, 42.6{\%} of the samples showed HER2/erbB-2 overexpression. Higher levels of expression were observed in samples from patients with clinically detectable metastases at initial presentation and at relapse. Expression of HER2/erbB-2 correlated with inferior event-free survival in patients with nonmetastatic disease (47{\%} versus 79{\%} at 5 years). In addition, HER2/erbB-2 expression was associated with significantly less tumor necrosis after preoperative chemotherapy as determined by the Huvos grading system. These data suggest that HER2/erbB-2 should be evaluated prospectively as a prognostic indicator and clinical trials using antibodies that target this receptor should be considered for the treatment of patients with osteogenic sarcoma.",
author = "Morris, {Carol D} and Richard Gorlick and Huvos, {Andrew G.} and Glenn Heller and Meyers, {Paul A.} and Healey, {John H.}",
year = "2001",
language = "English (US)",
pages = "59--65",
journal = "Clinical Orthopaedics and Related Research",
issn = "0009-921X",
publisher = "Springer New York",
number = "382",

}

TY - JOUR

T1 - Human epidermal growth factor receptor 2 as a prognostic indicator in osteogenic sarcoma

AU - Morris, Carol D

AU - Gorlick, Richard

AU - Huvos, Andrew G.

AU - Heller, Glenn

AU - Meyers, Paul A.

AU - Healey, John H.

PY - 2001

Y1 - 2001

N2 - Prognostic biologic factors that can be assessed at the time of diagnosis for patients with osteogenic sarcoma have not been identified. The current study was designed to evaluate the prognostic significance of the human epidermal growth factor receptor 2 as it relates to histologic response to preoperative chemotherapy and event-free survival. A retrospective immunohistochemical study was performed on material from patients who were newly diagnosed with osteogenic sarcoma who were treated according to the T12 protocol from the authors' institution between 1986 to 1993. Staining for HER2/erbB-2 was accomplished using standard monoclonal antibodies and methods. At the time of initial biopsy, 42.6% of the samples showed HER2/erbB-2 overexpression. Higher levels of expression were observed in samples from patients with clinically detectable metastases at initial presentation and at relapse. Expression of HER2/erbB-2 correlated with inferior event-free survival in patients with nonmetastatic disease (47% versus 79% at 5 years). In addition, HER2/erbB-2 expression was associated with significantly less tumor necrosis after preoperative chemotherapy as determined by the Huvos grading system. These data suggest that HER2/erbB-2 should be evaluated prospectively as a prognostic indicator and clinical trials using antibodies that target this receptor should be considered for the treatment of patients with osteogenic sarcoma.

AB - Prognostic biologic factors that can be assessed at the time of diagnosis for patients with osteogenic sarcoma have not been identified. The current study was designed to evaluate the prognostic significance of the human epidermal growth factor receptor 2 as it relates to histologic response to preoperative chemotherapy and event-free survival. A retrospective immunohistochemical study was performed on material from patients who were newly diagnosed with osteogenic sarcoma who were treated according to the T12 protocol from the authors' institution between 1986 to 1993. Staining for HER2/erbB-2 was accomplished using standard monoclonal antibodies and methods. At the time of initial biopsy, 42.6% of the samples showed HER2/erbB-2 overexpression. Higher levels of expression were observed in samples from patients with clinically detectable metastases at initial presentation and at relapse. Expression of HER2/erbB-2 correlated with inferior event-free survival in patients with nonmetastatic disease (47% versus 79% at 5 years). In addition, HER2/erbB-2 expression was associated with significantly less tumor necrosis after preoperative chemotherapy as determined by the Huvos grading system. These data suggest that HER2/erbB-2 should be evaluated prospectively as a prognostic indicator and clinical trials using antibodies that target this receptor should be considered for the treatment of patients with osteogenic sarcoma.

UR - http://www.scopus.com/inward/record.url?scp=0035169109&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035169109&partnerID=8YFLogxK

M3 - Article

C2 - 11154005

AN - SCOPUS:0035169109

SP - 59

EP - 65

JO - Clinical Orthopaedics and Related Research

JF - Clinical Orthopaedics and Related Research

SN - 0009-921X

IS - 382

ER -